Effects of Saw Palmetto Therapy on some Inflammatory Biomarkers in a Sample of Iraqi Male with Symptomatic Benign Prostatic Hyperplasia


  • Mazin Abdulridha Ateyah Clinical pharmacist, Baghdad, Iraq
  • Manal Khalid Abdulridha Department of Clinical Pharmacy/College of Pharmacy/ Mustansiriya University,Iraq
  • Munaim Jumaa Alkabee Consultant Urosurgeon, Alshahed Alsader Hospital/Baghdad/ Iraq




Benign prostatic hyperplasia, LUTS, Saw palmetto, Inflammatory biomarker


Background Saw palmetto contains powerful anti-inflammatory components commonly used in Benign prostatic hyperplasia (BPH) patients with symptoms. The current study was designed to assess the effectiveness of saw palmetto alone or supplementation


therapy with tamsulosin via measurement of some inflammatory biomarker in male with lower urinary tract symptoms (LUTS) consistent with (BPH).

Methods The present study is an interventional prospective randomized enrolled newly diagnosed patients with moderate to severe symptomatic BPH. The eligible 60 patients were allocated into (3) groups, each group with (20) patients; Group (1) treated with Saw palmetto cap (320 mg); Group (2) treated with  Saw palmetto cap (320 mg) and tamsulosin (0.4mg); Group (3) treated with tamsulosin (0.4mg), protocols to be given once daily for 12 weeks. Measurement of prostate specific antigen (PSA), C-reactive protein (CRP), and interleukin 6 (IL-6) was done.

Results There was significant decrease in the serum PSA, CRP and IL-6 level (P<0.01) in group1 and 2 patients only after treatment when compared to pretreatment.  Patients on combination therapy presented with high percent of change compared to other groups. No change in CRP and IL-6 level in patients on tamsulosin alone.

Conclusion From the findings of the present study, phytotherapy with Saw Palmetto alone or as supplement produced significant 3 months drop in both inflammatory markers, the total CRP level and IL-6 level. Also produced significant decrease in PSA level, and may substitute the conventional therapy in mild disease status.


- Gravas S, Cornu JN, Drake MJ, Gacci M, Gratzke C, Herrmann TRW, Management of non-neurogenic male lower urinary tract symptoms (LUTS).2018: 2588-817X.

- Claus G Roehrborn, MD, FACS, Benign Prostatic Hyperplasia: An Overview2005; 7(Suppl 9): S3–S14.

- Chughtai, B. et al. ‘Benign prostatic hyperplasia’, Nature Reviews Disease Primers. Nature Publishing Group. 2016 May 5; 2:16031. DOI: https://doi.org/10.1038/nrdp.2016.31

- Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian journal of urology. 2017 Jul 1;4(3):148-51. DOI: https://doi.org/10.1016/j.ajur.2017.06.004

- Bosch JR, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. European urology. 2008 Apr 1;53(4):819-27. DOI: https://doi.org/10.1016/j.eururo.2007.08.042

- Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. The Journal of urology. 2009 Oct 1;182(4):1458-62. DOI: https://doi.org/10.1016/j.juro.2009.06.047

- Ricco, J., & Prasad, S. The shrinking case for saw palmetto. The Journal of family practice. 2012, 61(7), 418–420.

- Fagelman, E., & Lowe, F. C. Saw Palmetto Berry as a Treatment for BPH. Reviews in urology.2001, 3(3), 134–138.

- Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2012. Issue 12. Art. No.:CD001423. DOI: https://doi.org/10.1002/14651858.CD001423.pub3

- Kim S. W. Phytotherapy: emerging therapeutic option in urologic disease. Translational andrology and urology. 2012, 1(3), 181–191.

- A Critical Analysis of PermixonTM in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement european urology supplements 5 (2006), 431–432. DOI: https://doi.org/10.1016/j.eursup.2006.02.006

- Kim TH, Lim HJ, Kim MS, Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews. Maturitas. 2012; 73(3):180‒185. DOI: https://doi.org/10.1016/j.maturitas.2012.07.007

- Chua T, Eise NT, Simpson JS, Ventura S. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility. J Ethnopharmacol. 2014, 14;152(2):283-91. DOI: https://doi.org/10.1016/j.jep.2013.12.030

- Andrea E. Gordon, M.D., And Allen F. Shaughnessy, Pharm.D, Harrisburg Family Practice Residency, Harrisburg, Pennsylvania. Saw Palmetto for Prostate Disorders. American Family Physician, Am Fam Physician. 2003, 15;67(06):1281-1283.

- Chittur S, Parr B, Marcovici G. Inhibition of Inflammatory Gene Expression in Keratinocytes Using a Composition Containing Carnitine, Thioctic Acid and Saw Palmetto Extract. Evidence-based Complementary & Alternative Medicine. 2011 Jan 1;8(1). DOI: https://doi.org/10.1093/ecam/nep102

- Williamson J, Qayyum T, Bryan N, Blunt L. UScale: a digital device for automatic urine volume measurement and frequency volume charting. Therapeutic Advances in Urology. 2019 Jan;11. DOI: https://doi.org/10.1177/1756287219875586

- Zhang, L., Li, H. Y., Li, W., Shen, Z. Y., Wang, Y. D., Ji, S. R., et al. An ELISA Assay for Quantifying Monomeric C-Reactive Protein in Plasma. Frontiers in immunology, 2018, 9, 511. DOI: https://doi.org/10.3389/fimmu.2018.00511

- Dhingra N, Bhagwat D. Benign prostatic hyperplasia: An overview of existing treatment. Indian journal of pharmacology. 2011 Feb;43(1):6. DOI: https://doi.org/10.4103/0253-7613.75657

- Khan A, Ali Z. Normal Ranges for Acute Phase Reactants (Interleukin-6, Tumour Necrosis Factor-alpha and C-reactive Protein) in Umbilical Cord Blood of Healthy Term Neonates at the Mount Hope Women's Hospital, Trinidad. West Indian Medical Journal. 2014 Sep 1;63(5). DOI: https://doi.org/10.7727/wimj.2012.133

- Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol. 2004; 163:1408–12. DOI: https://doi.org/10.1016/S0022-5347(05)67631-8

- Boyle P, Robertson C, Lowe F, Roehrborn C. Update meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int. 2004; 93:751–6. DOI: https://doi.org/10.1111/j.1464-410X.2003.04735.x

- Vela-Navarrete R, Garcia-Cardoso J, Barat JV, Manzarbeitia A,Lopez-Farre A.BPH and inflamematiom:pharmacological effect of PermixonTM on histological and molecular inflammatory markers. Result of a double-blind pilot clinical assay. Eur Urol. 2003; 44:549–55. DOI: https://doi.org/10.1016/S0302-2838(03)00368-3

- Curtis J Nickel, Daniel Shoskes, Claus G Roehrborn, And Mark Moyad, Nutraceuticals in Prostate Disease: The Urologist’s Role. 2008; 10(3): 192–206.

- Goldmann WH, Sharma AL, Currier SJ, Johnston PD, Rana A, Sharma CP. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. Cell Biol Int. 2001;25(11):1117-1124. DOI: https://doi.org/10.1006/cbir.2001.0779

- Cai T, Cui Y, Yu S, Li Q, Zhou Z, Gao Z. Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. American Journal of Men's Health. 2020 Mar;14(2). DOI: https://doi.org/10.1177/1557988320905407

- Yu ZJ, Yan HL, Xu FH, Chao HC, Deng LH, Xu XD, et al. Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. Frontiers in Pharmacology. 2020 May 8; 11:658. DOI: https://doi.org/10.3389/fphar.2020.00658

- Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, Tamsulosin, and Serenoa repens plus Tamsulosin treatment for patients with benign prostate hyperplasia. International Urology and Nephrology. 2007 Jul 1;39(3):879. DOI: https://doi.org/10.1007/s11255-006-9106-5

- Ryu YW, Lim SW, Kim JH, Ahn SH, Choi JD. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urologia internationalis. 2015;94(2):187. DOI: https://doi.org/10.1159/000366521

- Di Maida F, Mari A, Rubino R, Minervini A, Carini M, Siena G. A Prospective, Open-Label Comparison of Tamsulosin plus Serenoa repens and Bovine Colostrum versus Tamsulosin Alone in the Treatment of Benign Prostatic Hyperplasia. Urologia internationalis. 2020;104(5-6):351-5 DOI: https://doi.org/10.1159/000503735

- Abdel Bar FM. New chalcanonol glycoside from the seeds of saw palmetto: antiproliferative and antioxidant effects. Nat Prod Res. 2015;29(10):926-932. DOI: https://doi.org/10.1080/14786419.2014.960413

- Colado-Velázquez J III, Mailloux-Salinas P, Medina-Contreras J, Cruz-Robles D, Bravo G. Effect of SerenoaRepens on Oxidative Stress, Inflammatory and Growth Factors in Obese Wistar Rats with Benign Prostatic Hyperplasia. Phytother Res. 2015 ;29(10):1525-31. DOI: https://doi.org/10.1002/ptr.5406

- Bernichtein S, Pigat N, Camparo P, Latil A, Viltard M, Friedlander G, et al. Anti‐inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. The Prostate. 2015 May;75(7):706-22. DOI: https://doi.org/10.1002/pros.22953

- Paulis G. Inflammatory mechanisms and oxidative stress in prostatitis: the possible role of antioxidant therapy. Research and reports in urology. 2018, 10, 75–87. DOI: https://doi.org/10.2147/RRU.S170400

- Kantor ED, Lampe JW, Vaughan TL, Peters U, Rehm CD, White E. Association between use of specialty dietary supplements and C-reactive protein concentrations.Am J Epidemiol. 2012 Dec 1;176(11):1002-13. DOI: https://doi.org/10.1093/aje/kws186

- Adams JD, Lien EJ, Wang X. Saw palmetto, Serenoarepens, in the treatment of benign prostatic hyperplasia, mechanisms of action and reasons for its use. Pharm PharmacolInt J. 2015;2(1):1-4. DOI: https://doi.org/10.15406/ppij.2015.02.00007




How to Cite

Mazin Abdulridha Ateyah, Manal Khalid Abdulridha, & Munaim Jumaa Alkabee. (2022). Effects of Saw Palmetto Therapy on some Inflammatory Biomarkers in a Sample of Iraqi Male with Symptomatic Benign Prostatic Hyperplasia. Al Mustansiriyah Journal of Pharmaceutical Sciences, 21(1), 1–9. https://doi.org/10.32947/ajps.v21i1.774